

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	ISLAND PHARMACEUTICALS LIMITED
<b>ABN</b>	48 641 183 842

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mr Albert Hansen
<b>Date of last notice</b>	4 April 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Kesa Partners Inc – President and controller
<b>Date of change</b>	30 April 2024
<b>No. of securities held prior to change</b>	<p>Albert Hansen</p> <p>400,000 unlisted options exercisable at \$0.3625 expiring 30 April 2024</p> <p>Kesa Partners Inc</p> <p>11,104,034 fully paid ordinary shares</p> <p>166,667 options exercisable at \$0.06 expiring 14 March 2025</p>
<b>Class</b>	Unlisted options exercisable at \$0.3625 expiring 30 April 2024 ("unlisted options")

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

---

<b>Number acquired</b>	Nil
<b>Number disposed</b>	400,000 unlisted options
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>  Kesa Partners Inc	11,104,034 fully paid ordinary shares  166,667 options exercisable at \$0.06 expiring 14 March 2025
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of unlisted options

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	ISLAND PHARMACEUTICALS LIMITED
<b>ABN</b>	48 641 183 842

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Anna Lavelle
<b>Date of last notice</b>	4 April 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Dr Anna Lavelle <Armytage Advisory A/C>
<b>Date of change</b>	30 April 2024
<b>No. of securities held prior to change</b>	
Anna Lavelle	400,000 unlisted options exercisable at \$0.3625 expiring 30 April 2024
Dr Anna Lavelle <Armytage Advisory A/C>	140,000 fully paid ordinary shares 40,000 listed options exercisable at \$0.06 expiring 14 March 2025
<b>Class</b>	Unlisted options exercisable at \$0.3625 expiring 30 April 2024 ("unlisted options")
<b>Number acquired</b>	Nil

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

<b>Number disposed</b>	400,000 unlisted options
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>  Dr Anna Lavelle <Armytage Advisory A/C>	140,000 fully paid ordinary shares  40,000 listed options exercisable at \$0.06 expiring 14 March 2025
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of unlisted options

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – +Closed period

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	ISLAND PHARMACEUTICALS LIMITED
<b>ABN</b>	48 641 183 842

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr David Brookes
<b>Date of last notice</b>	4 April 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Tarandi 1996 Pty Ltd atf Dr DL Brookes Super A/C  David Lionel Brookes & Elisabeth Brookes atf Dr DL Brookes Personal Super Fund – trustee and beneficiary
<b>Date of change</b>	30 April 2024
<b>No. of securities held prior to change</b>	
David Brookes	400,000 unlisted options exercisable at \$0.3625 expiring 30 April 2024
Tarandi 1996 Pty Ltd atf Dr DL Brookes Super A/C	100,000 fully paid ordinary shares
David Lionel Brookes & Elisabeth Brookes atf Dr DL Brookes Personal Super Fund A/C	40,000 fully paid ordinary shares 40,000 listed options exercisable at \$0.06 expiring 14 March 2025

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	Unlisted options exercisable at \$0.3625 expiring 30 April 2024 ("unlisted options")
<b>Number acquired</b>	Nil
<b>Number disposed</b>	400,000 unlisted options
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>  Tarandi 1996 Pty Ltd atf Dr DL Brookes Super A/C  David Lionel Brookes & Elisabeth Brookes atf Dr DL Brookes Personal Super Fund A/C	100,000 fully paid ordinary shares  40,000 fully paid ordinary shares 40,000 listed options exercisable at \$0.06 expiring 14 March 2025
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of unlisted options

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	ISLAND PHARMACEUTICALS LIMITED
<b>ABN</b>	48 641 183 842

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr David Foster
<b>Date of last notice</b>	4 April 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Mr Terry Foster + Ms Vickey S Foster <Foster Living Account> - beneficiary  Citicorp Nominees Pty Limited – beneficiary
<b>Date of change</b>	30 April 2024

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>No. of securities held prior to change</b></p> <p>David Foster</p> <p>Mr Terry Foster + Ms Vickey S Foster &lt;Foster Living Account&gt;</p> <p>Citicorp Nominees Pty Limited</p>	<p>5,646,829 fully paid ordinary shares  177,778 unlisted options exercisable at \$0.3125 expiring 30 April 2024  177,778 unlisted options exercisable at \$0.3750 expiring 30 April 2024  177,778 unlisted options exercisable at \$0.4375 expiring 30 April 2024  500,000 listed options exercisable at \$0.06 expiring 14 March 2025</p> <p>85,152 fully paid ordinary shares  20,588 options exercisable at \$0.06 expiring 14 March 2025</p> <p>71,303 fully paid ordinary shares</p>
<p><b>Class</b></p>	<p>Unlisted options exercisable at \$0.3125 expiring 30 April 2024  Unlisted options exercisable at \$0.3750 expiring 30 April 2024  Unlisted options exercisable at \$0.4375 expiring 30 April 2024</p>
<p><b>Number acquired</b></p>	<p>Nil</p>
<p><b>Number disposed</b></p>	<p>177,778 unlisted options exercisable at \$0.3125 expiring 30 April 2024  177,778 unlisted options exercisable at \$0.3750 expiring 30 April 2024  177,778 unlisted options exercisable at \$0.4375 expiring 30 April 2024</p>
<p><b>Value/Consideration</b>  Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>Nil</p>
<p><b>No. of securities held after change</b></p> <p>David Foster</p> <p>Mr Terry Foster + Ms Vickey S Foster &lt;Foster Living Account&gt;</p> <p>Citicorp Nominees Pty Limited</p>	<p>5,646,829 fully paid ordinary shares  500,000 listed options exercisable at \$0.06 expiring 14 March 2025</p> <p>85,152 fully paid ordinary shares  20,588 options exercisable at \$0.06 expiring 14 March 2025</p> <p>71,303 fully paid ordinary shares</p>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Expiry of unlisted options</p>
---	-----------------------------------

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	ISLAND PHARMACEUTICALS LIMITED
<b>ABN</b>	48 641 183 842

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Paul MacLeman
<b>Date of last notice</b>	4 April 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Dalroar Pty Ltd <ATF MacLeman MacLeman Investment Trust> - Director of trustee and beneficiary of trust
<b>Date of change</b>	30 April 2024
<b>No. of securities held prior to change</b>	
Paul MacLeman	1 fully paid ordinary share
Dalroar Pty Ltd < ATF MacLeman MacLeman Investment Trust >	118,625 fully paid ordinary shares 2,325,000 unlisted options exercisable at \$0.3625 expiring 30 April 2024 33,572 options exercisable at \$0.06 expiring 14 March 2025
<b>Class</b>	Unlisted options exercisable at \$0.3625 expiring 30 April 2024 ("unlisted options")
<b>Number acquired</b>	Nil

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Number disposed</b>	2,325,000 unlisted options
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil
<b>No. of securities held after change</b>  Paul MacLeman  Dalroar Pty Ltd < ATF MacLeman MacLeman Investment Trust >	1 fully paid ordinary share  118,625 fully paid ordinary shares  33,572 options exercisable at \$0.06 expiring 14 March 2025
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Expiry of unlisted options

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

---

+ See chapter 19 for defined terms.

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.